Depression Outpatient – Autobahn ABX-002-MDD-2001

Written By Jamie Robison
 

About the Study

For adults with a diagnosis of Major Depressive Disorder (MDD) who continue to experience symptoms despite being on an antidepressant medication.

The goal of this study is to evaluate the efficacy, safety, and tolerability of ABX-002, an oral thyroid hormone receptor-beta (TRβ) agonist, as an adjunctive treatment for MDD. Participants will receive either ABX-002 or placebo in addition to their current antidepressant for approximately six weeks.

This study is sponsored by Autobahn Therapeutics, Inc.

 

Eligibility

You may be eligible to participate in this study if you:

  • are between the ages of 18–65 years old

  • meet DSM-5 criteria for Major Depressive Disorder (MDD)

  • are currently on a stable dose of an SSRI or SNRI antidepressant for at least 6 weeks

  • continue to experience depressive symptoms despite treatment

  • are willing to attend regular in-person study visits and follow-up assessments

 

If you are interested in participating in this clinical trial, please call our friendly staff at 801-871-5516 today. You can also fill out the contact form below.

Jamie Robison
Next

Schizophrenia | Outpatient | Neurocrine | NBI-1117568-SCZ3032